Sugi Predict

Sugi Predict / Compounds / SCHEMBL188375

SCHEMBL188375

SCHEMBL188375

CCC(N)c1ccc(Br)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SLC6A4 P31645 1/20 0.57
▸ DPP4 P27487 1/20 0.44
▸ HTR2A P28223 1/20 0.43
▸ MAOA P21397 1/20 0.41
▸ PYCR1 P32322 1/20 0.40
▸ CYP2A6 P11509 1/20 0.38
▸ CYP1A2 P05177 3/20 0.38
▸ ALOX5 P09917 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ CYP2D6 P10635 2/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ ALOX15 P16050 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL118924 1.00 SLC6A4 (0.57) SLC6A4DPP4HTR2AMAOAPYCR1
SCHEMBL896398 1.00 SLC6A4 (0.57) SLC6A4DPP4HTR2AMAOAPYCR1
Hydrochloric Acid SCHEMBL4934399 0.98 SLC6A4 (0.55) SLC6A4DPP4HTR2AMAOAPYCR1
SCHEMBL23092069 0.87 SLC6A4 (0.70) SLC6A4CYP1A2ALDH1A1CYP2D6CYP3A4
SCHEMBL9789908 0.82 SLC2A1 (0.42) SLC6A4DPP4HTR2AMAOAPYCR1
SCHEMBL3865060 0.78 SLC6A4 (0.59) SLC6A4MAOACYP2A6CYP1A2ALOX5
SCHEMBL8285910 0.78 SLC6A4 (0.59) SLC6A4CYP1A2ALDH1A1CYP2D6CYP3A4
SCHEMBL8286101 0.78 SLC6A4 (0.59) SLC6A4MAOACYP2A6CYP1A2ALOX5
SCHEMBL238408 0.78 SLC6A4 (0.59) SLC6A4CYP1A2ALDH1A1CYP2D6CYP3A4
SCHEMBL11659692 0.78 HTR2A (0.56) SLC6A4DPP4HTR2AMAOACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023214011-A1 ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES ENZYMICALS AG (DE) 2023-11-09 — — WO claimed
EP-4273254-A1 ENZYMATIC METHOD FOR PREPARING (R)-3-AMINO-4-ARYL-BUTANOIC ACID DERIVATIVES Enzymicals AG (DE) 2023-11-08 — — EP claimed
US-9879293-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2018-01-30 — — US claimed
US-20160177354-A1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS SAFC, INC. 2016-06-23 — — US claimed
EP-2462115-B1 ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS INFINITY PHARMACEUTICALS INC (US) 2016-01-06 — — EP claimed
EP-2744908-A1 ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE CHIRAL AMINES Embio Limited (IN) 2014-06-25 — — EP claimed
US-8703448-B2 Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS, INC. (US) 2014-04-22 — — US claimed
US-20140099682-A1 Enzymatic Synthesis of Optically Active Chiral Amines EMBIO LIMITED (IN) 2014-04-10 — — US claimed
WO-2013024453-A1 ENZYMATIC SYNTHESIS OF OPTICALLY ACTIVE CHIRAL AMINES EMBIO LIMITED (IN) 2013-02-21 — — WO claimed
CN-102574791-A Enzymatic transamination of cyclopamine analogs INFINITY PHARMACEUTICALS INC 2012-07-11 — — CN claimed
US-20120083607-A1 Enzymatic Transamination of Cyclopamine Analogs INFINITY PHARMACEUTICALS, INC. (US) 2012-04-05 — — US claimed
US-20260132147-A1 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIV (US) 2026-05-14 — — US disclosed
US-20260078417-A1 TRANSAMINASE BIOCATALYSTS CODEXIS, INC. (US) 2026-03-19 — — US disclosed
US-20260028600-A1 TRANSAMINASE POLYPEPTIDES CODEXIS INC (US) 2026-01-29 — — US disclosed
US-12479857-B2 Bax inhibitors and uses thereof CASE WESTERN RESERVE UNIVERSITY (US) 2025-11-25 — — US disclosed
EP-0404146-B1 Enantiomeric enrichment and stereoselective synthesis of chiral amines CELGENE CORP (US) 1996-03-20 — — EP disclosed
US-5300437-A Using omega-amino acid transaminase CELGENE CORPORATION (US) 1994-04-05 — — US disclosed
US-5169780-A Conversion to ketone in aqueous solution with amino acceptor and omega-amino acid acceptor; solvent extraction CELGENE CORPORATION (US) 1992-12-08 — — US disclosed
EP-0404146-A2 Enantiomeric enrichment and stereoselective synthesis of chiral amines CELGENE CORPORATION (US) 1990-12-27 — — EP disclosed
US-4950606-A CONTACTING IN AN AQUEOUS MEDIUM IN THE PRESENCE OF AN AMINO ACCEPTOR WITH AN OMEGA-AMINO ACID TRANSAMINASE TO CONVERT ONE OF AMINES TO KETONE CELGENE CORPORATION (US) 1990-08-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132147-A1 BAX INHIBITORS AND USES THEREOF BAX, BCL2, BAK1 SLC6A4 4724/4885DPP4 4556/4885HTR2A 4713/4885
US-20120083607-A1 Enzymatic Transamination of Cyclopamine Analogs TKT, TALDO1, BCHE SLC6A4 1280/4885DPP4 404/4885HTR2A 4028/4885
US-20260028600-A1 TRANSAMINASE POLYPEPTIDES GOT1, OAT, PEPD SLC6A4 260/4885DPP4 69/4885HTR2A 3838/4885
US-20260078417-A1 TRANSAMINASE BIOCATALYSTS XDH, AGXT, PEPD SLC6A4 717/4885DPP4 145/4885HTR2A 4156/4885
US-12479857-B2 Bax inhibitors and uses thereof BAX, TMBIM6, BCL2 SLC6A4 4820/4885DPP4 2749/4885HTR2A 4689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.